Drugs / ORM-12471
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01315899 | Mar → Dec 2011 | Raynaud disease | Orion Corporation, Orion Pharma | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORM-12471 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01315899 ↗ |
| Action | Inhibit | “α2C-adrenoceptor antagonist” PMID 24489014 ↗ Jan 2014 |
| Route | Oral | “At each treatment visit, each subject received a single oral dose of 30 mg or 100 mg of ORM-12741 or placebo.” PMID 24489014 ↗ Jan 2014 |